Immix Biopharma, Inc. IMMX
8.35 USD -0.22 (-2.57%)
At closeNov 10, 2026, 5:46 PM EST
8.14 -0.21 -2.51%
After hours · Nov 10, 5:46 PM ET
8.13 Day range 8.77
3.23 52-week range 14.47
- YTD
- +59.66%
- 1 year
- +157.72%
- Market cap
- 692.24M
- EPS (ttm)
- -0.86
- Shares out
- 71.19M
- Forward P/E
- -15.83
- YTD return
- +59.66%
- 1-year return
- +157.72%
- Volume
- 825.48K
- Avg volume
- 1.51M
- Open
- 8.37
- Previous close
- 8.57
- Day's range
- 8.13 – 8.77
- 52-week range
- 3.23 – 14.47
- Beta
- 0.11
- Analysts
- Strong Buy
- Price target
- 20.28 (+142.8%)
- Earnings date
- Nov 6, 2026
5D +0.34 (+4.24%)
Key statistics
- Enterprise value
- 775.45M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -25.39M
- Total cash
- 232.11M
- Total debt
- 1.00M
- Return on equity
- -34.18%
- Short % of float
- 17.59%
- 50-day average
- 10.38
- 200-day average
- 8.15
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 20.28 +142.8% upside
Now 8.35
- Target (low)
- 13.20
- Target (mean)
- 20.28
- Target (high)
- 27.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 6, 2026
Expected Nov 6, 2026. Consensus EPS estimate -0.19167.
Financials — quick view
IMMX Revenue — quarterly 0
IMMX Net income — quarterly -11.56M
IMMX EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2026 | Sep 30, 2026 | -0.18 | — | — | — |
| Aug 7, 2026 | Jun 30, 2026 | -0.17 | -0.18 | -0.01 | -5.88% |
| May 7, 2026 | Mar 31, 2026 | -0.21 | -0.18 | +0.03 | +14.29% |
| Mar 25, 2026 | Dec 31, 2025 | -0.21 | -0.27 | -0.06 | -28.57% |
| Nov 7, 2025 | Sep 30, 2025 | -0.19 | -0.24 | -0.05 | -26.32% |
| Aug 8, 2025 | Jun 30, 2025 | -0.21 | -0.22 | -0.01 | -4.76% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 11, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Aug 10, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 22, 2026 | Needham | init | — | Buy |
| Jun 18, 2026 | B of A Securities | init | — | Buy |
| Jun 17, 2026 | LifeSci Capital | init | — | Outperform |
| May 22, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immixbio.com
News
Immix Biopharma To Present An NXC-201 Abstract At American Society Of Hematology Annual Meeting, December 12-15 
Immix Biopharma's NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026 
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference 
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study 
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study 
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock 
Immix Biopharma (NASDAQ:IMMX) Stock Jumps 4.1% – Should You Buy? 
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript - Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
Your note
Sign in to keep a note on IMMX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS HELEN C | Director | Stock Award(Grant) | May 21, 2026 | 181,004 |
| BUCHAN MELISSA JANE | Director | Stock Award(Grant) | May 21, 2026 | 28,705 |
| CHANG NANCY T | Director | Stock Award(Grant) | May 21, 2026 | 925,130 |
| CHUDNOVSKY YEKATERINA | Director | Stock Award(Grant) | May 21, 2026 | 3,247,330 |
| HSU JASON | Director | Stock Award(Grant) | May 21, 2026 | 4,865,160 |
| MARQUET MAGDA | Director | Stock Award(Grant) | May 21, 2026 | 72,342 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Jupiter Topco LLC | 13.68% | 9,783,192 | 140.00M | Jun 29, 2026 |
| Saturn V Capital Management LP | 6.51% | 4,658,429 | 66.66M | Jun 29, 2026 |
| Eventide Asset Management LLC | 5.44% | 3,891,019 | 55.68M | Jun 29, 2026 |
| State Street Corporation | 4.19% | 2,996,935 | 42.89M | Jun 29, 2026 |
| Blackrock Inc. | 4.18% | 2,989,972 | 42.79M | Jun 29, 2026 |
| Deep Track Capital, Lp | 3.88% | 2,775,000 | 39.71M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 3.56% | 2,549,019 | 36.48M | Mar 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.93% | 2,096,255 | 30.00M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.80% | 1,285,595 | 18.40M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.49% | 1,067,981 | 15.28M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.64% | 456,667 | 6.53M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.52% | 370,703 | 5.30M | Jun 29, 2026 |